Search - tctmd.com

Displaying 21 - 40 of 111

Sort: Relevancy | Date

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Daily News

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Michael O'Riordan

June 18, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

News Daily News

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Caitlin E. Cox

March 24, 2020

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Marcus A. Banks

July 25, 2019

Advertisement

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

British Medical Groups Express Concern About Inclisiran Rollout

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Approved in Europe for Lowering LDL Cholesterol

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Inclisiran Data in NEJM Prompt Talk of What Comes Next

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Recurrent Events Common Among Young Patients With CAD

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Thwarted Access to PCSK9 Inhibitors Linked to Greater Risk of Major CV Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content